Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment ⊕
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.